Provided by Tiger Trade Technology Pte. Ltd.

Obseva Sa

0.1018
0.0000
Volume:- -
Turnover:- -
Market Cap:13.14M
PE:-0.11
High:0.1018
Open:0.1018
Low:0.1018
Close:0.1018
52wk High:0.2865
52wk Low:0.0800
Shares:129.07M
Float Shares:116.04M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9007
EPS(LYR):-0.7754
ROE:-373.98%
ROA:-50.26%
PB:-4.17
PE(LYR):-0.13

Loading ...

Company Profile

Company Name:
Obseva Sa
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.